The Company

“Biograil is a pre-clinical stage pharmaceutical company unlocking the potential of transforming the tremendous market of injectable pharmaceutical products into convenient oral capsules”

– Biograil CEO, Karsten Lindhardt

Recent News

Press Release: Biograil and Lilly Sign Collaboration and License Agreement
Biograil has signed a Collaboration and License Agreement with Eli Lilly
October 4, 2022
Read more
Press Release: Biograil Receives Innobooster Grant Providing Non-dilutive funding for BIONDDTM Technology Research and Activities in Preparations for Phase 1 clinical trials
Biograil recieves granting of government funds from Innobooster
March 14, 2022
Read more
Press Release: Biograil Forms International Scientific Advisory Board with Diverse Expertise to Support Further Optimization of the proprietary BIONDDTM Technology
After achieving proof of concept of BIONDDTM Technology in a pre-clinical model
March 1, 2022
Read more
See all